MILWAUKEE, Jan. 23, 2024 /PRNewswire/ — Ademi LLP is investigating Inhibrx (Nasdaq: INBX) in connection with its transaction with Sanofi.
Click here to learn how to join https://www.ademilaw.com/case/inhibrx-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
In the transaction, Inhibrx unitholders will receive only (i) $30.00 per share in cash, (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone and (iii) one SEC-registered, publicly listed, share of New Inhibrx per every four shares of Inhibrx common stock held. The transaction agreement unreasonably limits competing transactions for Inhibrx by imposing a significant penalty if Inhibrx accepts a competing bid. Inhibrx insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Inhibrx’s board of directors, and whether they are fulfilling their fiduciary duties to all unitholders.
If you own Inhibrx common units and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/inhibrx-inc.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
SOURCE Ademi LLP
